Medicare plans to restrict access to Alzheimer’s drug Aduhelm to patients in clinical trials Medicare plans to cover the controversial, pricey Alzheimer’s drug Aduhelm, but only for certain patients enrolled in clinical trials, the agency announced on Tuesday. The proposed move would likely mean some patients will not be able to access the drug. READ MORE If you’d like to stop receiving these alerts, click on the "update email preferences" link below. | 
No comments